Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-336 in Obese Individuals with Knee Osteoarthritis
NCT06833749Phase 2Recruiting
- Sponsor
- KeyBioscience AG
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of KBP-336 in obesity and osteoarthritis (OA) (4 arms), sponsored by KeyBioscience AG. Primary endpoints: Proportional change in body weight at 183 days and Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale at 183 days. Started Jan 2025; status: recruiting.
02
Drugs
KBP-336
03
Conditions
obesityosteoarthritis (OA)
Beyond the preview
Go deeper on NCT06833749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833749.